AMEDISYS (AMED) Company Report

The U.S. Justice Department has reached a proposed settlement for UnitedHealth Group's $3.3 billion acquisition of Amedisys, requiring the divestiture of 164 home health and hospice locations across 19 states.
These divestitures represent approximately $528 million in annual revenue and are intended to preserve competition in outpatient healthcare services.
Amedisys is required to pay a $1.1 million civil penalty and provide antitrust compliance training due to false certification during the investigation.
The settlement introduces operational complexity and potential delays to the merger's completion, including provisions for additional divestitures if regulatory approvals are not secured.

Aug 7, 2025, 5:08 PM

Amedisys Reports Q2 2025 Results Amid UnitedHealth Merger

AMED

Earnings

M&A

Amedisys reported strong financial results for Q2 2025, with net service revenue increasing to $621.9 million, a 5.2% rise from the previous year, and adjusted earnings per share rising to $1.54.
Despite improved adjusted EBITDA of $80.8 million, net income fell to $28.1 million from $32.3 million year-over-year, primarily due to merger-related expenses totaling $26.3 million in Q2 2025.
The company is currently in the process of merging with UnitedHealth Group and consequently did not hold a quarterly earnings call.
Most analysts maintain a cautious 'hold' rating on Amedisys stock, partly due to its relatively high price-to-earnings ratio of about 19 times projected earnings.

Jul 29, 2025, 10:23 PM

Amedisys Updates Divestiture Plans and Merger Transaction

AMED

M&A

Amedisys announced agreements for the sale of select home health and hospice care centers to affiliates of BrightSpring Health Services, with consummation contingent on the merger with UnitedHealth Group.
The company also entered into a separate agreement to sell additional home health care centers to affiliates of The Pennant Group, also subject to merger-related conditions.
The merger, which positions Amedisys as a wholly owned subsidiary of UnitedHealth Group, remains subject to multiple closing conditions and regulatory requirements, with executive oversight confirmed by CEO Richard Ashworth’s signature on May 1, 2025.

May 1, 2025, 12:00 AM

Amedisys Inc Reports Q1 2025 Financial Results

AMED

Earnings

M&A

Net service revenue increased by $23.4 million to $594.8 million compared to Q1 2024, indicating robust top-line growth.
Net income attributable to the company rose significantly to $61.0 million from $14.4 million in the prior period, with a GAAP diluted EPS of $1.84.
Non-GAAP measures also improved with an adjusted EBITDA of $68.8 million and higher adjusted net income and EPS, reflecting strong operational performance.
The company noted it will not host a quarterly earnings call due to its pending merger with UnitedHealth Group, marking an important strategic development.

Apr 23, 2025, 12:00 AM

Amedisys Reports Q4 2024 Financial Results & Strategic Initiatives

AMED

Earnings

M&A

Q4 2024 Performance: Consolidated revenue of $598.1M, net loss of $20.4M (merger-related expenses and a $48.4M impairment charge) alongside adjusted EPS of $0.96 and adjusted EBITDA of $54.6M
Full-Year 2024 Metrics: Net service revenue reached $2,348.3M, with adjusted EBITDA of $245.8M and adjusted net income of $142.7M (adjusted EPS of $4.32)
Organic Growth: Home Health same store admissions up 8%, Hospice ADC rising 0.5%, and High Acuity Care admissions increased by 29%
Strategic Initiatives: Pending merger with UnitedHealth Group Inc., efforts to optimize staffing ratios, and strong liquidity with net debt of $75.7M and $511.2M in revolving credit

Feb 26, 2025, 12:00 AM

Earnings Transcripts

Quarterly earnings call transcripts for AMEDISYS.

Get instant answers from SEC filings, earnings calls & more

Get instant analysis when filings drop